Board of Directors
Harry R. Jacobson
Dr. Jacobson, current Chairman of MedCare Investment Funds, is the former Vice Chancellor for Health Affairs at Vanderbilt University and CEO of Vanderbilt University Medical Center (VUMC). During Dr. Jacobson’s 11+ years of tenure, VUMC revenues grew from $750 million to $2.5 billion while delivering superior care at substantially lower costs seen in similar hospitals, its Federally-funded (NIH) research program moved from 24th to the top 10 in the country, and it opened over $1 billion of newly constructed research and patient care facilities. As a result, VUMC was recognized as a “most-wired” hospital as well as a U.S. News and World Report honor-roll hospital, and, most recently, as a Fortune 100 top place to work.
Dr. Jacobson has been a successful investor and entrepreneur, as well having founded or co-founded 10 companies. In addition, in his role at VUMC he participated in the oversight of technology transfer operations, which resulted in the creation of over two dozen companies.
Notable co-founded companies include Contact Software (the developer of Act!, the world’s leading contact management software), acquired by Symantec (SYMC:NASDAQ); Renal Care Group (RCG:NYSE), a leading dialysis service company, acquired by Fresenius (FMS:NYSE); Ambulatory Services of America (currently privately held), a diversified outpatient ancillary services provider currently providing dialysis and radiation oncology services (2009 revenue estimate > $200 million); and CeloNova Biosciences, a medical device company with two CE-approved and one FDA-approved products (2009 revenue estimate > $7 million).
Dr. Jacobson has been both a formal and informal advisor to several venture and private equity funds. He formerly served on the Board of Directors of Kinetic Concepts (KCI:NYSE) and Merck (MRK:NYSE).
Dr. Andrew W. Litt is CEO of Cornice Health Ventures, LLC., which helps others acquire and collaborate with healthcare service and technology companies. Dr. Litt is also an Operating Partner with The Vistria Group, a healthcare-oriented private equity firm, and was an Executive-in-Residence with GE Healthcare and GE Ventures focusing on Artificial Intelligence and Deep Learning. He also advises startup and growth companies on strategy, business development, and financing.
Dr. Litt is a neuroradiologist with recognized expertise in neurovascular imaging. He was a magna cum laude graduate of Brown University where he was elected a member of Phi Beta Kappa. He received his Doctor of Medicine degree from NYU and then completed an internship, residency, and fellowship there. He is a member of the NYU School of Medicine’s Alpha Omega Alpha honor society.
Mr. Lyles is the President of MedCare Investment Funds with over 20 years of experience establishing health care companies. Mr. Lyles has managed an investment portfolio for over twenty years, including both public and large private companies, and serves as an Advisory Director of Majesty Hedge Funds. He also serves on numerous for-profit and non-profit Boards of Directors.
Mr. Lyles’ primary responsibility is President of a private holding company, which oversees both strategic and operational issues for various portfolios. Mr. Lyles has helped organize each fund in the MedCare Investment Funds group and has served as President of each fund since 1991. As a founding partner, Mr. Lyles was an active member of management in founding Renal Care Group along with Dr. Jacobson and the late Sam Brooks. Mr. Lyles, through his role as President of MedCare Investment Funds, has founded and established numerous health care companies. Examples include companies in the health care services sector (an ambulatory services company partnering with physicians and providing dialysis and radiation oncology services; an outpatient imaging services and management company), the medical technology sector (a medical device company with two CE Marks-approved and one FDA-approved device, and a company developing a device to treat glaucoma and presbyopia), and the health care information technology sector (a physician practice software company focused on women’s health and an early stage health care informatics company creating electronic medical records for Regional Health Information Organizations (RHIO), large health care systems, hospitals and multisite practices, a benefits management company utilizing proprietary software).
Mr. Lyles has also helped found and build multiple high tech businesses primarily involving data transmission over cellular technology. Mr. Lyles is an Attorney and was appointed a Briefing Attorney for the Chief Justice of the Supreme Court of Texas from 1983-1984. Prior to attending law school, he was employed by KPMG Peat Marwick. Mr. Lyles is a Certified Public Accountant and has written material for the Texas State Bar and has been a speaker for the State Bar of Texas and the Dallas Bar.
Gregory Oberholtzer, current Senior Managing Director, WP Global Partners has over 30 years of broad investment advisory experience with a focus on alternative asset management and financial product structuring for institutional clients.
Prior to joining WP Global, he was a Director of WestAM, where he was responsible for their small and middle market buyouts, special situations, and co-investments, and was a member of the Private Equity Executive Committee and Investment Committee. Prior to WestAM, Mr. Oberholtzer previously served as the Managing Director and Portfolio Manager of Forstmann-Leff International’s (FLI) Global Derivatives Group and was a Senior Vice President of Products and Strategies. Prior to FLI, Mr. Oberholtzer was a Director of Jefferies Analytical Trading Group at Jefferies Group, where he was involved in product structure and fund management in equities and listed derivatives. Mr. Oberholtzer has served as the president of two private financial services companies and was active in a successful family business for several years.
He is a board member or observer of Australis, BrightFarms, Illumitex, Monogram Foods, and VoloAgri, among other portfolio companies, and serves as an advisory board member of more than two dozen invested funds. He holds a B.B.A. from George Washington University.
Chief Executive Officer
Mr. Umbel is Chief Executive Officer of Seno Medical Instruments, Inc. Tom Umbel brings more than 30 years of medical device and diagnostics leadership experience to Seno Medical. He has lead several start-up companies, including one through a successful acquisition. He has also managed large organizations through significant growth leading both the strategic development and M&A efforts in his previous roles.
Tom was most recently the VP of Business Development for Bioventus, a privately held ortho-biologics company in Durham, NC. Tom has led the Business Development efforts at both Bioventus and Hologic, the largest dedicated Women’s Health company in the U.S. Tom’s role in managing mergers and acquisitions helped to grow Hologic from a small single-product company with $100 million in revenue to a large diversified company with more than $2.5 billion in sales in his 15 years with the company.
Prior to Hologic, Tom was the President of Direct Radiography Corp. (DRC). He led the development and commercialization of the digital x-ray detector technology, which he ultimately sold to Hologic in 1999. This company’s technology became the core to Hologic’s market leading digital mammography system and was the engine to Hologic’s significant growth.
Prior to DRC, Tom worked at Sterling Diagnostic Imaging for 3 years and DuPont for 20 years. At those two companies, Tom held senior management positions in operations, engineering, sales and marketing.
Tom has a BS in Chemical Engineering from Grove City College.